GI Pharmacology · Module 1 of 8

Acid Suppression and Peptic Ulcer Disease

Parietal cell physiology · Proton pump inhibitors · H2 receptor antagonists · Helicobacter pylori eradication · Cytoprotective agents

Three inputs converge on one pump: histamine (ECL cells → H2 receptor → Gs → cAMP → PKA), gastrin (G cells → CCK-B receptor → Ca²⁺ + ECL histamine release), and acetylcholine (vagal → M3 → Gq → Ca²⁺) all drive the H⁺/K⁺ ATPase to secrete H⁺ into the gastric lumen to pH ~1.0; histamine is quantitatively dominant and mediates a large portion of the response to all three stimuli, which is why H2 blockers blunt the parietal cell response to gastrin and vagal signals as well.
PPIs are prodrugs activated in the acidic secretory canaliculus → reactive sulfenamide covalently bonds to H⁺/K⁺ ATPase cysteine → irreversible block; must be taken 30–60 min before the first meal (pump must be actively secreting to be accessible); full effect takes 3–5 days; suppresses ~90% of pump capacity vs. ~65% for H2RAs; pantoprazole preferred with clopidogrel (minimal CYP2C19 inhibition); omeprazole/esomeprazole inhibit CYP2C19 → reduce clopidogrel activation.
H2RAs are competitive reversible H2 blockers; tolerance develops within 1–2 weeks (hypergastrinemia upregulates H2 receptors); cimetidine inhibits CYP1A2/2C9/2D6/3A4 and blocks androgen receptors (gynecomastia, impotence) — never preferred; famotidine has negligible CYP inhibition and no anti-androgenic effects and is always the preferred H2RA; ranitidine was withdrawn 2020 (NDMA contamination).
H. pylori eradication regimens run 14 days (not 7): triple therapy (PPI + amoxicillin + clarithromycin) when local clarithromycin resistance <15%; bismuth quadruple therapy (PPI + bismuth + metronidazole + tetracycline) when resistance >15% or prior macrolide exposure — achieves >90% eradication regardless of clarithromycin resistance; confirm eradication with urea breath test or stool antigen test 4 weeks post-therapy; stop PPI 2 weeks before testing; stop antibiotics/bismuth 4 weeks before; serology cannot confirm eradication.
Cytoprotective agents: antacids (Al/Mg hydroxide) neutralize acid transiently (1–2 hours) and chelate fluoroquinolones, tetracyclines, iron, bisphosphonates — separate by 2 hours; sucralfate polymerizes at low pH → physical barrier at ulcer crater for up to 6 hours, does not neutralize acid, avoid in severe renal impairment (aluminum), separate from fluoroquinolones/warfarin/phenytoin/digoxin/thyroid hormone; misoprostol (PGE1 analog) replaces COX-1 prostaglandins depleted by NSAIDs and is an absolute contraindication in pregnancy (uterine contractions → miscarriage/preterm labor).

CCK-B = cholecystokinin B receptor · cAMP = cyclic adenosine monophosphate · COX-1 = cyclooxygenase-1 · CYP2C19 = cytochrome P450 2C19 · ECL = enterochromaffin-like · H2RA = histamine H2 receptor antagonist · NDMA = N-nitrosodimethylamine · NSAID = nonsteroidal anti-inflammatory drug · PKA = protein kinase A · PPI = proton pump inhibitor · PGE1 = prostaglandin E1 · ZES = Zollinger-Ellison syndrome

Parietal Cell: Three Inputs, One Pump

Input 1

Histamine

ECL cells → H2 receptor → Gs → cAMP → PKA → pump activation; quantitatively dominant input

Input 2

Gastrin

Antral G cells → CCK-B receptor on parietal cell + ECL cells → Ca²⁺ and amplified histamine release

Input 3

Acetylcholine

Vagal fibers → M3 receptor → Gq → Ca²⁺; also promotes ECL histamine release

Final Effector

H⁺/K⁺ ATPase

Exchanges H⁺ for luminal K⁺, consuming ATP → luminal pH ~1.0

Acid-Suppressive Drug Classes Compared

Feature	Proton Pump Inhibitors	H2 Receptor Antagonists	Notes
Target	H⁺/K⁺ ATPase (the pump itself)	Histamine H2 receptor on parietal cell	PPIs act downstream of all three receptor inputs
Binding	Irreversible covalent (sulfenamide-cysteine)	Competitive reversible	PPIs suppress ~90%; H2RAs ~65% of acid output
Onset	Delayed; 3–5 days to full effect	Rapid (1–2 hours)	H2RAs better for on-demand symptom relief
Timing rule	30–60 min BEFORE first meal — non-negotiable	With or without food	PPI taken after meal encounters far fewer active pumps
Tolerance	No	Yes (1–2 weeks) — limits long-term use	Hypergastrinemia upregulates H2 receptors
Preferred agent	Any; pantoprazole if on clopidogrel	Famotidine — always preferred over cimetidine	Cimetidine: CYP1A2/2C9/2D6/3A4 inhibition + androgen receptor block

Proton Pump Inhibitor Key Pharmacology

Prodrug Mechanism

Acid Activation in Canaliculus

Absorbed in small intestine → reaches parietal cell via bloodstream
Concentrated in acidic secretory canaliculus → acid converts prodrug to reactive sulfenamide
Covalent disulfide bond to cysteine on luminal face of H⁺/K⁺ ATPase → irreversible
Pump recovery requires new protein synthesis: ~18 hours
Must be taken before meal: food activates parietal cells, inserting resting pumps into canaliculus

CYP2C19 Pharmacogenomics

Metabolizer Status Matters

Ultrarapid metabolizers: rapid clearance → low drug exposure → treatment failure risk (especially H. pylori eradication)
Poor metabolizers: 2–5× higher drug levels → greater acid suppression
Rabeprazole: least CYP2C19-dependent (mostly non-enzymatic metabolism)
Pantoprazole: minimal CYP2C19 inhibition → preferred when patient is on clopidogrel
Omeprazole / esomeprazole: inhibit CYP2C19 → reduce clopidogrel bioactivation → reduced antiplatelet effect

Long-Term Adverse Effects

Monitor for These

Hypomagnesemia: impaired intestinal Mg²⁺ absorption; oral Mg supplementation does not fix it — stop PPI
Clostridioides difficile risk increased (gastric acid kills ingested organisms)
Calcium malabsorption: CaCO₃ requires acid for dissolution → use calcium citrate instead
Rebound acid hypersecrecy on abrupt discontinuation (hypergastrinemia → ECL hyperplasia) → taper
B12 malabsorption with very long-term use (acid required for protein-bound B12 release)

Helicobacter pylori Eradication

First-Line Regimens (14 Days)

Choose Based on Local Resistance

Triple therapy (clarithromycin resistance <15%): PPI + amoxicillin + clarithromycin × 14 days; PPI twice daily
Bismuth quadruple (resistance >15% or prior macrolide): PPI + bismuth + metronidazole + tetracycline × 10–14 days; achieves >90% eradication regardless of clarithromycin resistance
14 days outperforms 7 days by 5–10 percentage points; do not shorten
CYP2C19 ultrarapid metabolizers: double the PPI dose or use rabeprazole (antibiotics less effective at low pH)
Confirm eradication: urea breath test or stool antigen test 4 weeks after completing therapy

Diagnostic Testing — Avoid False Negatives

Urea Breath Test / Stool Antigen Test

Urea breath test: patient ingests labeled urea → H. pylori urease hydrolyzes it → labeled CO₂ detected in exhaled breath; >95% sensitivity and specificity; standard for confirming eradication
Stool antigen test (monoclonal antibody): equivalent accuracy to urea breath test
Stop PPI at least 2 weeks before testing (false negatives)
Stop antibiotics and bismuth at least 4 weeks before testing
Serology: cannot confirm eradication — antibody titers persist months to years after cure; do not use for post-treatment testing

Cytoprotective Agents

Antacids

Acid Neutralization — Transient

Al(OH)₃: constipating; Mg(OH)₂: laxative; combinations balance GI effects
Duration only 1–2 hours when taken on empty stomach
Role: on-demand relief of mild intermittent heartburn only; no role in ulcer healing
Chelate fluoroquinolones, tetracyclines, iron, bisphosphonates → markedly reduce absorption; separate by ≥2 hours

Sucralfate

Physical Barrier at Ulcer Crater

Aluminum salt of sucrose octasulfate; polymerizes at low pH → viscous paste adheres to ulcer base; barrier protects for up to 6 hours per dose
Stimulates prostaglandin synthesis and mucus secretion; does NOT neutralize acid
Stress ulcer prophylaxis in ventilated ICU patients (may carry lower VAP risk than PPIs)
Avoid in severe renal impairment (aluminum accumulation)
Separate from fluoroquinolones, warfarin, phenytoin, digoxin, thyroid hormone by 2 hours

Misoprostol

PGE1 Analog — Absolute CI in Pregnancy

Synthetic PGE1 analog: replaces COX-1-derived prostaglandins depleted by NSAIDs → stimulates mucus, bicarbonate, mucosal blood flow; mildly inhibits acid secretion
NSAID-induced ulcer prevention: ~40% reduction; enteric-coated NSAID formulations do NOT prevent ulcers (systemic prostaglandin depletion, not topical acid, is the mechanism)
Dose-dependent diarrhea and cramping limit tolerability
Absolute contraindication in pregnancy: stimulates uterine contractions via myometrial PGE receptors → miscarriage, preterm labor; use PPI instead in women of childbearing potential

Critical Rules — PPI Timing and Misoprostol

PPI timing is the single most common correctable source of treatment failure: the drug must reach the parietal cell while it is actively secreting, which requires food stimulation. Take 30–60 minutes before the first meal. A PPI taken at bedtime or at breakfast without the pre-meal interval encounters a largely resting pump pool and produces substantially less acid suppression. For twice-daily regimens, the second dose goes 30–60 minutes before the evening meal, not at bedtime.

Misoprostol is FDA Pregnancy Category X. Even at the gastroprotective dose (200 mcg four times daily) it can cause first-trimester miscarriage or preterm labor. It is deliberately used in obstetrics for cervical ripening and medical termination of pregnancy — which is precisely why inadvertent exposure is dangerous. Before prescribing for any indication, confirm absence of pregnancy and ensure reliable contraception. In women of childbearing potential requiring NSAID gastroprotection, a PPI is uniformly preferred.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter on Gastrointestinal Pharmacology	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill; 2023
Schubert ML, Peura DA	Control of gastric acid secretion in health and disease	Gastroenterology. 2008;134(7):1842–1860
Sachs G et al.	The gastric H,K ATPase as a drug target: past, present, and future	J Clin Gastroenterol. 2007;41(Suppl 2):S226–S242
Shin JM, Sachs G	Pharmacology of proton pump inhibitors	Curr Gastroenterol Rep. 2008;10(6):528–534
Furuta T et al.	CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection	Drug Metab Pharmacokinet. 2005;20(3):153–167
Bhatt DL et al.	Clopidogrel with or without omeprazole in coronary artery disease (COGENT trial)	N Engl J Med. 2010;363(20):1909–1917
Chey WD et al.	ACG clinical guideline: treatment of Helicobacter pylori infection	Am J Gastroenterol. 2017;112(2):212–239
Malfertheiner P et al.	Management of Helicobacter pylori infection — the Maastricht V/Florence Consensus Report	Gut. 2017;66(1):6–30
Graham DY et al.	Prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer with misoprostol	Lancet. 1988;2(8623):1277–1280